Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Mohammad Jad Moussa , Adrienne H. Chen , Allison K. Grana , Jianjun Gao , Amishi Yogesh Shah , Paul Gettys Corn , Nizar M. Tannir , Sangeeta Goswami , Jianbo Wang , John C. Araujo , Ashish M. Kamat , Neema Navai , Curtis Alvin Pettaway , Mehrad Adibi , Bogdan Czerniak , Charles C. Guo , Arlene O. Siefker-Radtke , Matthew T Campbell , Omar Alhalabi
Background: Adenocarcinomas of the urinary tract, including urachal (UA) and non-urachal (NUA) subtypes, are rare tumors. Triplet regimens combining gemcitabine, a taxane or 5-fluorouracil (5-FU)/leucovorin (L), and cisplatin (P), have been developed. Methods: We retrospectively reviewed records of patients receiving frontline (1L)GemFLP (Gemcitabine 200 mg/m2 IV on days 1 and 5; 5-FU 200 mg/m2 IV on days 1, 2, 3, 4, 5; L 10mg/m2 IV on days 1, 2, 3, 4, 5; P 20mg/m2 IV on days 1, 2, 3, 4, 5) in advanced UA and NUA at MDACC between 2003 and 2023. Advanced disease is defined as Sheldon stages IVA/IVB in UA and TNM stage IV in NUA. Imaging-based best overall responses (BOR) were complete (CR), partial (PR), stable (SD), progressive (PD) or non-evaluable (NE). Overall response rate (ORR) covers CR + PR, while disease control rate (DCR) covers CR + PR + SD. We report overall survival (OS) and progression-free survival (PFS) from GemFLP start. Results: Baseline characteristics of UA (n=40) and NUA (n=28) are in Table. In UA, bladder dome was primary location in 39 (97.5%). NUA pts had either bladder (11, 39.3%) or urethral (17, 60.7%) origin. BOR in 1L GemFLP are shown in Table. In UA, ORR is 20% and DCR is 72.5%. Median OS (mOS) is 19.8 months (95% CI: 12.2 - 30.6) and median PFS (mPFS) is 5.3 mo (95% CI: 3.1 – 6.3). In UA, pts with CR, PR, or SD have a significantly longer mOS than pts with PD [26 mo (16.2 – 35.6) vs. 7.7 mo (2.67 – 11.9), log-rank p<0.0001]. Meanwhile, in NUA, ORR is 35.7% and DCR is 75%. mOS is 12.95 mo (95% CI: 7.1-20.2) and mPFS is 5.3 mo (1.93 – 7.6). A similar significant survival benefit is seen in NUA pts with disease control versus pts with PD [17.6 mo (12.6 – 25.9) vs. 5 mo (2.63 – 7.1), p<0.0001]. Surgical consolidation was offered for 6 UA pts (3 PR, 3 SD), 3 of whom were regional N+ only, and for 4 NUA pts (1 CR, 1 PR, 2 SD) who were all regional N+ only. All except one showed residual pathological disease. Conclusions: 1L GemFLP is an active regimen in advanced UA and NUA, with a DCR of >70%. Pts with disease control (CR, PR, or SD) have a clear survival benefit compared to non-responders. 1L GemFLP might offer chances at surgical consolidation after disease control for pts with regional node-positive only disease, with larger cohorts needed to confirm findings.
Variable | UA (n=40) | NUA (n=28) | |
---|---|---|---|
Characteristics | |||
Age at mets, median [ICR] | 57.3 [45.4 – 62.7] | 64 [59 – 67] | |
Race, n (%) | White | 32 (80%) | 18 (64.3%) |
Black | 6 (15%) | 7 (25%) | |
Other | 2 (5%) | 3 (10.7%) | |
Prior surgery for localized disease, n (%) | 22 (55%) | 7 (25%) | |
Visceral mets at 1L GemFLP, n (%) | Any | 31 (77.5%) | 17 (60.7%) |
Lung | 16 (40%) | 8 (28.6%) | |
Liver | 4 (10%) | 1 (3.6%) | |
Peritoneum | 15 (37.5%) | 1 (3.6%) | |
Bone | 3 (7.5%) | 6 (21.4%) | |
Nodal-only mets at 1L GemFLP, n (%) | 9 (22.5%) | 11 (39.3%) | |
Outcomes | |||
BOR to 1L GemFLP, n (%) | CR | 0 (0%) | 1 (3.6%) |
PR | 8 (20%) | 9 (32.1%) | |
SD | 21 (52.5%) | 11 (39.3%) | |
PD | 7 (17.5%) | 5 (17.9%) | |
NE | 4 (10%) | 2 (7.1%) | |
Surgical consolidation after 1L GemFLP, n (%) | 6 (15%) | 4 (14.3%) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Takahiro Tsushima
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Anant Ramaswamy
2023 ASCO Gastrointestinal Cancers Symposium
First Author: So Heun Lee
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Vaibhav Sahai